Patent application number | Description | Published |
20090111794 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase - Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A | 04-30-2009 |
20090325927 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor - Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H | 12-31-2009 |
20100292208 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE - Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene A | 11-18-2010 |
20110159563 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase - Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity. | 06-30-2011 |
20110190503 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase - Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity. | 08-04-2011 |
20110257153 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase - Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A | 10-20-2011 |
20110263639 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase - Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A | 10-27-2011 |
Patent application number | Description | Published |
20090093467 | THERAPEUTIC COMPOSITIONS AND METHODS - The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof. | 04-09-2009 |
20090093482 | THERAPEUTIC COMPOSITIONS AND METHODS - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 04-09-2009 |
20140343062 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 11-20-2014 |
20140343063 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS - The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof. | 11-20-2014 |
20150216873 | METHODS OF TREATING PATIENTS CO-INFECTED WITH HIV AND TUBERCULOSIS - The disclosure describes methods for treatment of patients co-infected with HIV and tuberculosis, wherein the patient receives effective amounts of elvitegravir, an antimycobacterial agent and a CYP inhibitor. | 08-06-2015 |
Patent application number | Description | Published |
20090324729 | USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT - The invention provides a composition comprising, a compound of formula (I): | 12-31-2009 |
20100331331 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF - The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof. | 12-30-2010 |
20110009411 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 01-13-2011 |
Patent application number | Description | Published |
20100199092 | SENSOR DERIVED AUTHENTICATION FOR ESTABLISHING PEER-TO-PEER NETWORKS - Methods, systems and devices for generating an authentication key are provided. Two or more communications devices can generate an authentication key by monitoring a physical stimulus that is experienced by both devices (e.g., a common physical stimulus). Each device can then use an identical, predetermined algorithm to generate a common authentication key based on the stimulus. The devices can use the common authentication key to establish a secure network. | 08-05-2010 |
20130229930 | PROXIMITY-BASED WIRELESS HANDSHAKING FOR CONNECTION ESTABLISHMENT - A first network device can implement functionality to establish a proximity-based wireless connection with a second network device. It can be determined whether the second network device is within a threshold detection distance from the first network device based on a signal strength associated with RF signals received from the second network device or based on detecting RF saturation at the first network device. Device credentials associated with the first network device can be transmitted to the second network device at a reduced transmit power level in response to determining that the second network device is within the threshold detection distance from the first network device. A communication link can be established between the first network device and the second network device based, at least in part, on the device credentials associated with the first network device and device credentials received from the second network device. | 09-05-2013 |
20150046991 | SENSOR DERIVED AUTHENTICATION FOR ESTABLISHING PEER-TO-PEER NETWORKS - Methods, systems and devices for generating an authentication key are provided. Two or more communications devices can generate an authentication key by monitoring a physical stimulus that is experienced by both devices (e.g., a common physical stimulus). Each device can then use an identical, predetermined algorithm to generate a common authentication key based on the stimulus. The devices can use the common authentication key to establish a secure network. | 02-12-2015 |